Adaptive Immunity — Antigens and Antibodies

Q1 — Sample Band 6 response (8 marks), annotated

Season 1 (primary response): In Season 1, all participants were naive — no previous exposure to H3N2 strain A. Dendritic cells phagocytosed the virus and presented HA antigen fragments on MHC II. Clonal selection identified the rare B cell clone whose BCR matched a strain-A HA epitope from a pool of millions of naive B cells — a process requiring 7–14 days. During this lag phase, the virus replicated freely, causing symptomatic illness in 88% of participants. Clonal expansion produced plasma cells secreting IgG, reaching a modest peak of only 65 AU, and also produced memory B cells. The low peak reflects the relatively small number of selected naive cells and the time lag before sufficient antibody was produced. [1 — primary response mechanism with naive B cells; 1 — lag → illness explanation]

Season 2 (secondary response): By Season 2, all participants carried memory B cells specific for the H3N2 strain-A HA antigen, formed during Season 1. The matched vaccine introduced strain-A HA antigens as a second exposure. Memory B cells activated within hours without needing to repeat clonal selection from the naive pool — they were already pre-selected and present in much greater numbers. They rapidly differentiated into plasma cells producing large amounts of high-affinity IgG, peaking at 410 AU (6.3× higher than Season 1). The rapid antibody production cleared the antigen before significant viral replication occurred, explaining the sharp drop in fever rate from 88% to 12%. [1 — memory B cell mechanism correctly described; 1 — links 410 AU and low illness to speed of secondary response]

Season 3 (antigenic variation): Season 3 introduced H3N2 strain B, with a mutated HA protein. The mutation changed the amino acid sequence of the HA epitope that the Season 1/2 memory B cells and antibodies were specific for. BCRs and antibodies are highly specific — their variable regions are shaped to bind one particular epitope. Because the mutated HA presented a different epitope, existing memory B cells and circulating antibodies from Seasons 1–2 did not recognise it effectively. The immune system had to mount what was effectively a new primary response, selecting from the naive B cell pool again. This explains why the antibody peak (78 AU) and illness rate (81%) in Season 3 resembled Season 1 rather than Season 2. [1 — antigenic variation correctly applied to BCR specificity; 1 — explains why Season 3 ≈ Season 1]

Evaluation — does memory provide complete permanent protection? The data do not support this claim. Memory B cells provide highly effective, rapid, and amplified protection — but only against the exact antigen (or a very similar one) that selected the original B cell clone. When the pathogen mutates the relevant epitope (as in Season 3), existing memory becomes ineffective. The data show protection is antigen-specific and cannot extend to structurally different antigens, even from the same virus species. [1 — explicit evaluation of completeness and permanence]

Why annual vaccination is necessary: The data show that a new HA variant (strain B) circumvents existing H3N2 strain-A memory, effectively resetting immunity to a primary-level response. Influenza A mutates its HA and NA surface antigens every year through antigenic drift. Annual vaccination introduces antigens from the strains predicted to dominate that season, generating new memory B cells specific to the current variant — providing a targeted secondary-level response when that strain circulates. Without annual vaccination, each new season's dominant strain may present epitopes sufficiently different that existing memory cells cannot recognise them. [1 — links annual vaccination to antigen specificity and antigenic drift]

Marking criteria.

• 1 mark — Season 1: correctly identifies naive B cell clonal selection lag as the cause of slow, modest primary response and high illness rate.
• 1 mark — Season 1: links the 7–14 day lag to viral replication and clinical symptoms.
• 1 mark — Season 2: correctly identifies memory B cells as the basis of the faster, stronger response (410 AU vs 65 AU) without re-selecting from naive B cells.
• 1 mark — Season 2: links rapid high-titre antibody production to low illness rate (12%).
• 1 mark — Season 3: correctly applies antigenic variation — mutated HA epitope not recognised by existing memory BCRs/antibodies.
• 1 mark — Season 3: explains why Season 3 data resembles Season 1 (effectively a new primary response).
• 1 mark — Evaluation: clearly states that immunological memory does NOT provide complete permanent protection — it is specific and fails when the pathogen's epitope changes.
• 1 mark — Annual vaccination: correctly links annual vaccination to antigenic drift and the need to generate new memory cells for each season's variant.

Q2 — Sample Band 6 response (7 marks), annotated

The claim contains a kernel of biological truth but is largely inaccurate and oversimplified. [1 — overall evaluative judgement]

What is defensible: The claim is correct that after defeating an infection, the immune system retains the capacity to respond more rapidly and powerfully if the same pathogen returns. For pathogens with stable antigens (e.g. varicella-zoster virus), the immunity generated after a primary infection is indeed long-lasting and can prevent illness for decades. [1 — correctly identifies the defensible element with a named example]

What is wrong — antibody permanence: Antibody levels do not stay elevated "forever" after an infection. Plasma cells — the short-lived effector B cells that produce circulating antibodies — survive only days to weeks after the primary response. Antibody titres decline substantially over months. A person who had chickenpox 20 years ago does not have high circulating anti-varicella antibody levels — but they are still protected. The claim is factually wrong to attribute ongoing immunity to permanently elevated circulating antibodies. [1 — correctly refutes "forever" with plasma cell lifespan and antibody decline]

What is wrong — the role of memory B cells: Memory B cells are not a mere "backup" — they are the primary cellular basis of long-term immunity. They are long-lived lymphocytes that persist for years to decades in lymph nodes and bone marrow. They carry the same BCR as the originally selected B cell. On re-exposure, they activate within hours and flood the bloodstream with IgG antibodies within 1–3 days — before circulating antibody levels alone could stop the infection. Calling memory cells a "backup" fundamentally misrepresents their role. [1 — correctly identifies and explains the actual central role of memory B cells]

What is wrong — "complete, lifelong protection": Immunological memory is antigen-specific. It provides effective protection only against the same antigen (or a very similar one) that initially selected the B cell clone. If the pathogen mutates its surface antigens significantly (antigenic drift in influenza A, for example), existing memory B cells may not recognise the new epitopes. In such cases, the immune system must mount an essentially primary response against the new variant. This is exactly why annual influenza vaccination is required — the virus mutates its haemagglutinin antigen every year. [1 — correctly qualifies with conditions under which lifelong immunity does and does not apply]

Biologically defensible reformulation: After infection or vaccination, clonal selection and expansion of the specific B cell clone produces both short-lived plasma cells (which generate the immediate antibody response) and long-lived memory B cells (which persist for years and constitute the cellular basis of immunological memory). On re-exposure to the same antigen, memory B cells rapidly differentiate into plasma cells, generating a much faster and stronger secondary antibody response that usually prevents illness. This memory is antigen-specific: it remains effective for pathogens with stable surface antigens (e.g. varicella-zoster) but may be insufficient if the pathogen mutates its antigens significantly, as occurs with influenza A. [1 — accurate reformulation using precise terminology: clonal selection, plasma cells, memory B cells, secondary response, antigen-specific]

Named example: Varicella-zoster virus causes chickenpox; memory B cells formed during a childhood primary infection persist for life and prevent re-infection in most people, illustrating durable antigen-specific immunity for a pathogen with stable surface antigens. [1 — named example correctly used]

Marking criteria.

• 1 mark — States an overall evaluative judgement (e.g. "partly true but largely misleading" or equivalent).
• 1 mark — Identifies the one defensible element (rapid, enhanced secondary response after a primary infection; names a valid example such as varicella-zoster).
• 1 mark — Correctly refutes "antibodies stay in blood forever" using plasma cell lifespan and antibody titre decline over time.
• 1 mark — Correctly identifies memory B cells as the primary cellular basis of long-term immunity (not a backup) — explains their persistence and role in rapid secondary response.
• 1 mark — Correctly identifies conditions where immunity is and is not lifelong — antigen-specific; fails when pathogen epitopes mutate (antigenic drift/variation).
• 1 mark — Provides a biologically accurate reformulation of the claim using precise lesson terminology (clonal selection, plasma cells, memory B cells, antigen-specific, secondary response).
• 1 mark — Uses a named example from the lesson correctly (varicella-zoster for durable immunity; or influenza for limitations of memory when antigen mutates).